Guidelines for the management of either hypertension or hyperlipidaemia have been widely published. However, recent data have shown the high frequency of an abnormal lipid profile in hypertensive subjects. We have therefore surveyed 195 general practitioners throughout Britain to determine current communitybased attitudes and management approaches to hypertension with coexistent hypercholesterolaemia. Routine screening for lipids in hypertensive subjects was recommended by 40% of respondents. First-line antihypertensive drug choices were influenced by the knowledge of a hypercholesterolaemia, with preference for drugs known to have no adverse effects on the lipid profile. When first-choice drug failed to effectively lower blood pressure, the additional drug or the substitute choices were not influenced by the metabolic profiles of the alternative selected. The current wide choice of antihypertensive drugs and the complexity of metabolic complications of treatment plus the relationship of risk factor clustering has made the formulation of management strategies very difficult. This was supported by the finding that 88% of respondents in our survey felt that there was a clear need for consensus management guidelines for the treatment of hypertension with coexistent hypercholesterolaemia.
Introduction
In recent years there has been an unprecedented proliferation of drugs for the treatment of hypertension. With the continuing high incidence of cardiovascular disease, in particular coronary heart disease (CHD), guidelines for the management of the individual risk factors -hypertension':" or hyperlipidaemiav", have been published. These consensus strategies provide a framework for identification and treatment of subjects at risk of cardiovascular disease.
There are increasing numbers of reports showing the frequency of abnormal lipid profiles in hypertensive groups to be at least 50%7-9. This finding may in part be explained by a pathophysiological link between hypertension and glucose and lipid metabolism lO and by the well documented association between antihypertensive drug therapy and disturbances in glucose and lipid metabolism!'. Therefore when choosing treatment for hypertension, an important consideration ought to bean assessment of whether there is a coexistent hypercholesterolaemia 12 • The present study surveyed in the primary care setting attitudes and management approaches to hypertension with coexistent hypercholesterolaemia. The aim was to ascertain whether contemporary prescribing practice in Britain was reflecting the complex interplay between risk factors associated with hypertension and its treatment.
Methods
One hundred and ninety-five general practitioners were surveyed in February 1990 through the computerized link of the Meditex network about their approach to treatment of mild hypertension and hypercholesterolaemia. The Meditex* network is a panel of general practitioners and covers an equal distribution of urban and non-urban practices throughout the health regions of Britain; the sizes of the practices were also balanced. The survey consisted of a questionnaire. The following questions were posed: (1) Attitudes to management of hypertension Whether coronary heart disease (CHD) can be reduced by reducing blood pressure (BP) alone? Relative importance of other factors contributing to CHD in the drug treatment of a new hypertensive patient? Which patients were routinely screened for a lipid profile? Whether guidelines for the treatment ofhypertension with hypercholesterolaemia would be useful?
(2) Drug treatment choices First and seconddrug choices in treating BP over the range 160/95-180/105 mmHg in a patient younger than 70 years with or without hypercholesterolaemia?
[Drug choices were listed in alphabetical order and included monotherapy of either single drug or fixed drug combinations. The drug choices were ACE inhibitor, alpha-blocker, beta-blocker, calcium antagonist, centrally acting drug, diuretic, fixed drug combinations or vasodilator. Fixed drug combinations suggested were ACE inhibitor/diuretic, beta-blocker/ diuretic or calcium antagonist/beta-blocker].
All 195 general practitioners in the network responded through their individual computer links. Their answers are reported as a relative response (%) rate to each question.
Results (1) Attitudes to management of hypertension Sixty-four per cent of the surveyed general practitioners considered that CHD reduction was· not achieved by reducing BP alone. The most important factor considered to be contributing to CHD, other than hypertension, was smoking followed by family history of cardiovascular disease, lipids and body weight ( Figure 1 In the treatment of BP over the range 160/95-180/105 mmHg the most frequent drug choices were beta-blockers (27%), ACE inhibitors (26%), diuretics (23%) and calcium antagonists (11%); 5% of respondents did not initiate drug therapy (Table 1) . With coexistent hypercholesterolaemia, treatment choices were substantially different; the main preference was for the use of an ACE inhibitor r38%) followed by a calcium antagonist (17%); with both alpha-and betablockers next (each 13%). There was about a 50% reduction in preference for diuretics (12%) and for fixed drug combinations (3%) ( Table 1) .
Where the first choice drug failed to effectively lower BP, 70% of the respondents added in a drug from another group, with a diuretic being the most popular choice (48%) ( Table 2) ; 23% substituted with an alternative drug ( the most favoured choice was a fixed drug combination (29%) incorporating either a diuretic or a beta-blocker; 7% continued with the same drug. When faced with coexistent hypercholesterolaemia and failure of firstline treatment to control BP, an additional drug was chosen by 63% of respondents (with a diuretic being the most popular) and substitution of drug by 27% (with an ACE inhibitor most favoured) while 11% continued with the initial drug choice (Tables 2 and 3 ).
Discussion
Coronary heart disease remains a major cause of morbidity and mortality in industrialized countries with the detection and treatment of modifiable risk factors, such as hypertension and hypercholesterolaemia, as well as cigarette smoking, continuing to be important public health issues. As CHD is the most common complication of hypertension, attention to other risk factors may be as important as lowering the arterial pressure with respect to this complication. Detailed clinical studies have demonstrated that untreated hypertensive subjects have a clustering of risk factors, often with abnormalities of glucose and lipid metabolism'", while epidemiological data have highlighted the synergistic effect of hypercholesterolaemia with hypertension'<".
This study has shown that most of the surveyed general practitioners recognize that BP reduction alone does not lower the incidence of CHD and that besides hypertension, smoking was the most important risk factor, followed by family history, lipids and weight (Figure 1) . When questioned about reasons for routine lipid measurements only 40% of respondents considered that the presence of hypertension would justify screening. This reveals a lack of impact of the concept of synergy between alterations in the lipid profile and hypertension with CHD risk, as well as a lack of awareness of the high frequency of abnormal lipid levels in hypertensive subjects":", Treatment of hypertension has clearly demonstrated reductions in pressure related complications of stroke, heart failure, aneurysm and renal failure. However, the major randomized trials of antihypertensive drug therapy in mild hypertension have not shown significant benefit on CHD reduction". Many antihypertensive drugs induce adverse changes in glucose and lipid metabolism", These drug-induced metabolic effects may have offset the benefits gained by lowering arterial pressure and account for the lack of benefit on CHD reduction'", By contrast treatment of hypercholesterolaemia has clearly conferred benefit on CHD reduction in both primary and secondary intervention trials!" with more recent data clearly showing that regression of coronary artery disease may occur within 2 years with a reduction in the plasma cholesterol concentration!". Furthermore, a small increase in cholesterol level is positively associated with an increased CHD risk-", while a 1% reduction in plasma cholesterol confers the benefit of a 2% reduction in CHD events. Due to the linear relationship without threshhold effect between the cholesterol level and CHD, our present survey on antihypertensive drug choices only sought to define attitudes and drug choices in the presence or absence of a proven hypercholesterolaemia.
Diuretics, beta-blockers and centrally acting drugs have been shown to adversely affect the lipid profile in the short-and long-term!'. By contrast ACE inhibitors and calcium antagonists appear to have no adverse effect on lipid metabolism!', while alphablockers appear to have small beneficial effects on the atherogenic lipid profile!',
The data from this survey show that when treating hypertension in the presence of a raised cholesterol, the knowledge that there were additional metabolic disturbances did influence the frequency and types of drugs used. While there was an overall reduction by 50% in drugs known to adversely affect lipid profiles (ie a beta-blocker or diuretic either alone or in fixed combination with another antihypertensive drug) these drugs still accounted for first-line choices in 26% of respondents.
If the first-line drug treatment was ineffective, the general trend was to add another drug. The additional choice was not influenced by the metabolic profile of the drug selected as 61% chose a drug with documented adverse effects on lipids; these included either a beta-blocker, centrally acting drug, diuretic alone or in fixed combination ( Table 2) . Interestingly When an alternative drug was chosen, a lower percentage (44%) selected drugs with known adverse effects on lipids. Furthermore, in treatment choices for hypertension unaccompanied by a raised cholesterol where the first-line drug failed to lower BP, a drug with known adverse effects on lipids was the additional choice made by 77% of the respondents, while substitution with an alternative was made by 61%.
Undoubtedly, familiarity with older well-tried drugs may explain some of the trends in choices of treatment reported in this study. Availability of newer drugs has increased the opportunities for choice and has allowed Journal of the Royal Society of Medicine Volume 84 April 1991 205 individualization of therapeutic regimens to take the place of the traditional 'step-care' approach. However, the complexities of metabolic complications of drug therapy and the relationship of risk factor clustering has made the management choices for many practitioners very difficult. The prudent choice of effective drug therapy for the patient with hypertension and coexistent hypercholesterolaemia may confer a significant reduction in CHD risk and be an important determinant in the long-term clinical outcome of these patients. It would 'appear that objective guidelines in the management choice are warranted.
